Orchid Pharma has received final USFDA approval for its generic version of rasagiline tablets used in the treatment of Parkinson’s disease. The company expects to launch this products in the fourth quarter of fiscal 2016-17. The drug rasagiline mesylate tablets are indicated for the treatment of signs and symptoms of idiopathic Parkinson’s disease. It has an estimated market size of over USD 300 million and limited generic competition. Rasagiline tablets are sold under the brand AZILECT by Teva Pharmaceutical Industries.
Company Profile : Orchid Chemicals And Pharmaceuticals Ltd
Leave a Reply